Akcea Therapeutics (NASDAQ: AKCA) has promoted Kyle Jenne to chief commercial officer. Jenne joined Boston-based Akea in 2017 as US commercial head. His appointment comes month after a corporate shakeup that led to the departure of three executives. Akcea is working to commercialize inotersen (Tegsedi), a drug approved by the FDA last year as a treatment for the nerves damage caused by the rare disease hereditary transthyretin amyloidosis.
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Xconomy Insight · Special Report
Insights, wisdom, and inspiration on what it takes
From Our Editors · Special Report
Key indicators & expert insight from industry leaders
Xconomy
